Arrow (1963) hypothesized that demand-side moral hazard induced by health insurance leads to supply-side expansions in healthcare markets. Capturing these effects empirically has been challenging, as non-marginal insurance expansions are rare and detailed data on healthcare labor and capital is...

Informal care has drawn much attention among scholars and policymakers as it concerns an essential but hard to evaluate resource of welfare. Albeit several studies addressed the monetary value of informal care, differences in the relationship between caregivers and recipients have often been...

Arrow (1963) hypothesized that demand-side moral hazard induced by health insurance leads to supply-side expansions in healthcare markets. Capturing these effects empirically has been challenging, as non-marginal insurance expansions are rare and detailed data on healthcare labor and capital is...

Background: Economic evaluation (EE) is a dynamically advancing knowledge area of health economics. It has been conceived to provide evidence for allocating scarce resources to gain the best value for money. The problem of efficiency of investments becomes even more crucial with advances in...

Il presente lavoro analizza i principali fatti caratterizzanti i comparti dei farmaci generici puri e dei branded off-patent in Italia, attraverso i dati relativi alle compravendite del 2002 (tramite il SSN e per via privata) di tutti i farmaci a base delle 10 molecole a brevetto scaduto che...

Aktuell weisen die Krankenkassen und der Gesundheitsfonds Überschüsse von über 20 Mrd. Euro auf. Für Daniel Bahr, Bundesminister für Gesundheit, eröffnen diese Überschüsse – neben der Abschaffung der Praxisgebühr – Spielräume für Prämien. Die zentrale Herausforderung an eine...

Klaus-Dirk Henke, TU Berlin und Wolfram Richter, TU Dortmund, identifizieren in ihrem Kommentar gravierende Ordnungsdefizite beim Wettbewerb im deutschen Gesundheitswesen. Sie gehen solchen Defiziten im Bereich der GKV nach und benennen konkrete Mängel, die von der Politik behoben werden sollten.

Dopo il rilascio dell'Autorizzazione all'Immissione in Commercio, un farmaco "H", prima di divenire concretamente disponibile in ospedale, deve completare una trafila che può differire da Regione a Regione, e addirittura, all'interno di una stessa Regione, da ASL ad ASL o da ospedale ad...

Se evalúa mediante un modelo de Markov la costo-efectividad de la plasmaféresis previa a la timectomía en el tratamiento de la miastenia gravis comparada con la timectomía sola. La perspectiva fue la del pagador, incluyendo todos los costos directos. Los datos de efectividad y riesgo de...

The commonwealth cannot be equated with the state nor can the common good of society be sustained by government action alone. Rather, the activities of all members of society are crucial importance. Such private sector activities also define the development of national healthcare markets in the...